Perifosine gets FDA fast-track status as colorectal cancer drug

04/5/2010 | Bloomberg Businessweek

The FDA gave fast-track review designation to perifosine, Aeterna Zentaris and Keryx Biopharmaceuticals' experimental treatment for refractory advanced colorectal cancer. Perifosine already has orphan-drug status as well as fast-track status for its use against multiple myeloma.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA